Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 380 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Botox Injection Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction

NCT01591746
View directory record Official record
Conditions
Breast Cancer, Pain, Postoperative, BRCA1 Mutation, BRCA2 Mutation, Breast Diseases, Neoplasms
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 19, 2026, 6:06 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome

NCT06729151
View directory record Official record
Conditions
Bladder Pain Syndrome, Female Sexual Dysfunction
Interventions
Onabotulinum toxin A, Conservative management (dietary and behavioral)
Drug · Behavioral
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 99 Years · Female only
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 19, 2026, 6:06 AM EDT
Completed Phase 3 Interventional Results available

A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine

NCT01662492
View directory record Official record
Conditions
Migraine Disorders
Interventions
Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2, Placebo (Normal Saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Phoenix, Arizona • Fullerton, California • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 19, 2026, 6:06 AM EDT
Terminated Phase 2 Interventional Results available

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy

NCT04965311
View directory record Official record
Conditions
Pancreatic Carcinoma
Interventions
Botulinum Toxin Type A
Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 19, 2026, 6:06 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002

NCT02334436
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
Biological · Other
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 19, 2026, 6:06 AM EDT
Not listed Phase 1 Interventional

New Approaches in Evaluating Patients' Response to Botulinum Toxins in the Treatment of Chronic Neck Pain and Back Pain

NCT02008136
View directory record Official record
Conditions
Cervicalgia, Low Back Pain
Interventions
Botulinum Toxins
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 19, 2026, 6:06 AM EDT
Not listed Phase 4 Interventional

Efficacy Study of Botox for Depression

NCT01556971
View directory record Official record
Conditions
Major Depression
Interventions
Botox, Saline Solution
Drug
Lead sponsor
Capital Clinical Research Associates, LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chevy Chase, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 19, 2026, 6:06 AM EDT
Terminated Not applicable Interventional Results available

Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial

NCT00822926
View directory record Official record
Conditions
Pain
Interventions
Botulinum Toxin Type A, Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 19, 2026, 6:06 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency

NCT01700387
View directory record Official record
Conditions
Chronic Migraine
Interventions
onabotulinumtoxinA, Topiramate, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 19, 2026, 6:06 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

NCT00461292
View directory record Official record
Conditions
Overactive Bladder
Interventions
botulinum toxin Type A (200U), botulinum toxin Type A (300U), Normal saline (Placebo); botulinum toxin Type A (200U), Normal saline (Placebo); botulinum toxin Type A (300U)
Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Middlebury, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 19, 2026, 6:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of OnabotulinumtoxinA (BOTOX®) on Stress

NCT06778421
View directory record Official record
Conditions
Stress (Psychology), Stress, Healthy Adult Female Participants, Stress, Psychologic, Stress, Psychological Cumulative, Stress, Physiological, Stress Response, Stress Levels, Stress Perception
Interventions
Intramuscular injection, OnabotulinumtoxinA (Botox®) Injections, Sodium Chloride
Procedure · Drug · Other
Lead sponsor
Center for Advanced Facial Plastic Surgery
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 19, 2026, 6:06 AM EDT
Completed Phase 3 Interventional

Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

NCT03608397
View directory record Official record
Conditions
Cervical Dystonia
Interventions
DaxibotulinumtoxinA for injection, Placebo
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
44
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 19, 2026, 6:06 AM EDT
Terminated Phase 4 Interventional Results available

Real World Effectiveness of Eptinezumab in Participants With Migraine

NCT05284019
View directory record Official record
Conditions
Migraine
Interventions
Eptinezumab, Erenumab, Onabotulinumtoxin-A, Fremanezumab, Galcanezumab
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Gilbert, Arizona • Stamford, Connecticut • Palmetto Bay, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 19, 2026, 6:06 AM EDT
Completed Phase 2 Interventional

Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm

NCT00234507
View directory record Official record
Conditions
Blepharospasm
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
14
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 19, 2026, 6:06 AM EDT
Recruiting Phase 4 Interventional

Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A

NCT04305743
View directory record Official record
Conditions
Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary, Urinary Urge Incontinence, Urinary Frequency More Than Once at Night, Nocturia
Interventions
OnabotulinumtoxinA 100 UNT
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 19, 2026, 6:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines

NCT02718118
View directory record Official record
Conditions
Glabellar Lines, Wrinkles
Interventions
Dysport reconstituted at 1.5 mL (0.05 mL/injection), Dysport reconstituted at 2.5 mL (0.08 mL/injection)
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Greenwood Village, Colorado • Coral Gables, Florida • Smithtown, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 19, 2026, 6:06 AM EDT
Completed Phase 4 Interventional Results available

Neurotoxin and Physical Therapy

NCT02177617
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Botox injection, Physical Therapy, Transcranial magnetic stimulation (TMS)
Drug · Behavioral · Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 19, 2026, 6:06 AM EDT
Completed Phase 2 Interventional Results available

Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin

NCT00971620
View directory record Official record
Conditions
Cutaneous Leiomyomas, Hereditary Leiomyomatosis and Renal Cell Cancer
Interventions
Botulinum toxin type A, Placebo
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 19, 2026, 6:06 AM EDT
Completed Phase 4 Interventional

A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction

NCT03199534
View directory record Official record
Conditions
Pelvic Pain, Dyspareunia, Pelvic Floor Dysfunction
Interventions
Botulinum toxin A 50u, Botulinum toxin A 100u, Botulinum toxin A 150u
Drug
Lead sponsor
EvergreenHealth
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 19, 2026, 6:06 AM EDT
Completed Phase 2 Interventional

Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

NCT04401176
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Heparin & Alkalinized Lidocaine Bladder Instillation, Onabotulinum Toxin A
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 19, 2026, 6:06 AM EDT
Not yet recruiting Phase 2 Interventional

Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa

NCT07756346
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
13 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 19, 2026, 6:06 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of the Use of Botox on Acne

NCT00765375
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Botulinum Neurotoxin Type A, Bacteriostatic saline
Drug
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 19, 2026, 6:06 AM EDT
Terminated Phase 4 Interventional Results available

A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder

NCT03078270
View directory record Official record
Conditions
Anxiety Disorder Social, Anxiety
Interventions
botulinum toxin A, Placebo
Drug · Other
Lead sponsor
Daniel Lieberman
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 19, 2026, 6:06 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines

NCT05766683
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
onabotulinumtoxinA at a depth of 2mm, onabotulinumtoxinA at a depth of 4mm
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 19, 2026, 6:06 AM EDT